1. Anti-infection
  2. HBV
    Reverse Transcriptase

Adefovir dipivoxil (Synonyms: GS 0840)

Cat. No.: HY-B0255 Purity: 98.50%
Data Sheet SDS Handling Instructions

Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body.

For research use only. We do not sell to patients.
Adefovir dipivoxil Chemical Structure

Adefovir dipivoxil Chemical Structure

CAS No. : 142340-99-6

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $77 In-stock
50 mg $70 In-stock
100 mg $120 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body. Target: NRTIs; HBV Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body. Adefovir Dipivoxil is used for treatment of hepatitis B and herpes simplex virus infection [1-3]. Adefovir Dipivoxil is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (primarily ALT) or histologically active disease. Adefovir Dipivoxil is a failed treatment for HIV[3, 4].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00441974 GlaxoSmithKline Chronic Hepatitis B December 2006 Phase 4
NCT00324961 GlaxoSmithKline Chronic Hepatitis B January 2006 Phase 4
NCT01353742 GlaxoSmithKline Hepatitis B, Chronic February 21, 2011 Phase 1
NCT01329419 GlaxoSmithKline Hepatitis B August 2004
NCT01436539 Jun Cheng|Sanofi|Fujian Cosunter Pharmaceutical Co. Ltd|Capital Medical University Chronic Hepatitis B September 2011 Phase 4
NCT02327689 Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China Hepatitis B, Chronic|Fibrosis January 2015 Phase 4
NCT00347009 GlaxoSmithKline Hepatitis B, Chronic|Cirrhosis|Fibrosis|Chronic Hepatitis B May 2005 Phase 4
NCT00644761 Gilead Sciences Hepatitis B February 2004 Phase 2
NCT00489151 Hospital Authority, Hong Kong|The University of Hong Kong Hepatitis B June 2005
NCT00645294 Gilead Sciences Hepatitis B February 2003 Phase 1|Phase 2
NCT00403585 GlaxoSmithKline Hepatitis B, Chronic|Chronic Hepatitis B July 2006 Phase 4
NCT00307242 Thomas Jefferson University Chronic Hepatitis B May 2005 Phase 4
NCT00002206 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT01581242 Bukwang Pharmaceutical Healthy April 2012 Phase 1
NCT00001082 National Institute of Allergy and Infectious Diseases (NIAID) Cytomegalovirus Infections|HIV Infections December 1996 Phase 3
NCT00095121 Gilead Sciences Chronic Hepatitis B June 2004 Phase 3
NCT00641082 Bukwang Pharmaceutical HBeAg(-) Chronic Hepatitis B With Compensated Liver Function February 2008 Phase 4
NCT00002128 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT00002426 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00002161 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00000843 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT00042393 Gilead Sciences Chronic Hepatitis B
NCT00455091 National Health Research Institutes, Taiwan|National Taiwan University Hospital|Chang Gung Memorial Hospital|Taipei Veterans General Hospital, Taiwan|Mackay Memorial Hospital|Taichung Veterans General Hospital|Changhua Christian Hospital|National Cheng-Kung University Hospital|Kaohsiung Veterans General Hospital.|Kaohsiung Medical University Hepatocellular Carcinoma May 2007
NCT00071201 Gilead Sciences Chronic Hepatitis B June 2003 Phase 3
NCT00753467 Huntington Medical Research Institutes|InterMune Hepatitis B September 2008 Phase 2
NCT00115245 Novartis|Novartis Pharmaceuticals Chronic Hepatitis B November 2004 Phase 3
NCT00187746 University of California, San Francisco Other Conditions That May Be A Focus of Clinical Attention August 2005 Phase 4
NCT00661076 Hoffmann-La Roche Hepatitis B, Chronic August 2008 Phase 3
NCT01146808 Columbia University|Gilead Sciences Hepatitis B|Liver Transplantation March 2006 Phase 1|Phase 2
NCT00002220 Merck Sharp & Dohme Corp.|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00606099 Novartis Chronic Hepatitis B November 2007 Phase 4
NCT00002419 Gilead Sciences|Glaxo Wellcome|Dupont Applied Biosciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00973219 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Chronic Hepatitis B September 2009
NCT00002219 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00002379 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT01300234 GlaxoSmithKline Hepatitis B March 2011 Phase 3
NCT00002398 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00002184 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00033163 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Hepatitis B Phase 2
NCT00376259 Novartis Hepatitis B January 2007 Phase 3
NCT00002234 Gilead Sciences|Bristol-Myers Squibb|Glaxo Wellcome|Dupont Applied Biosciences HIV Infections Phase 2
NCT00023153 National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) HIV Infections|Chronic Hepatitis B August 2001 Phase 3
NCT00672867 Bukwang Pharmaceutical Patients With LC-B December 2007 Phase 3
NCT00051077 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Hepatitis B|Hepatitis C Phase 2
NCT02075294 Ying-Jie Ji|Beijing 302 Hospital Hepatitis B, Chronic January 2010
NCT00002346 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT00371761 Merck Sharp & Dohme Corp. Hepatitis B, Chronic (CHB) September 2006 Phase 3
NCT02598063 Hoffmann-La Roche Hepatitis B, Chronic October 2005 Phase 4
NCT01521975 Third Affiliated Hospital, Sun Yat-Sen University|Guangdong Provincial People's Hospital|Guangzhou 8th People's Hospital Hepatitis B, Chronic September 2011 Phase 4
NCT01720238 Beijing Friendship Hospital|Peking University First Hospital|Peking University People's Hospital|Beijing YouAn Hospital|Beijing Tiantan Hospital|Beijing Ditan Hospital|Peking Union Medical College Hospital|Beijing 302 Hospital Liver Cirrhosis|Hepatitis B March 2012
NCT02327416 Tongji Hospital|Xiamen Amoytop Biotech Co., Ltd. Hepatitis B, Chronic October 2014 Phase 3
NCT00000892 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT02826070 Nanfang Hospital of Southern Medical University|Major Science and Technology Special Project of China Twelfth-Five-Year Project|Novartis Hepatitis B, Chronic April 2015 Phase 4
NCT00000912 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT01264354 Bukwang Pharmaceutical Chronic Hepatitis B March 2010 Phase 4
NCT02965859 Guangzhou Yipinhong Pharmaceutical CO.,LTD Chronic Hepatitis B December 2012 Phase 2
NCT00001087 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00000885 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00810524 Sun Yat-sen University Hepatitis B, Chronic January 2007 Phase 4
NCT00441974 GlaxoSmithKline Chronic Hepatitis B December 2006 Phase 4
NCT00324961 GlaxoSmithKline Chronic Hepatitis B January 2006 Phase 4
NCT01353742 GlaxoSmithKline Hepatitis B, Chronic February 21, 2011 Phase 1
NCT01329419 GlaxoSmithKline Hepatitis B August 2004
NCT01436539 Jun Cheng|Sanofi|Fujian Cosunter Pharmaceutical Co. Ltd|Capital Medical University Chronic Hepatitis B September 2011 Phase 4
NCT02327689 Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China Hepatitis B, Chronic|Fibrosis January 2015 Phase 4
NCT00347009 GlaxoSmithKline Hepatitis B, Chronic|Cirrhosis|Fibrosis|Chronic Hepatitis B May 2005 Phase 4
NCT00644761 Gilead Sciences Hepatitis B February 2004 Phase 2
NCT00489151 Hospital Authority, Hong Kong|The University of Hong Kong Hepatitis B June 2005
NCT00645294 Gilead Sciences Hepatitis B February 2003 Phase 1|Phase 2
NCT00403585 GlaxoSmithKline Hepatitis B, Chronic|Chronic Hepatitis B July 2006 Phase 4
NCT00307242 Thomas Jefferson University Chronic Hepatitis B May 2005 Phase 4
NCT00002206 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT01581242 Bukwang Pharmaceutical Healthy April 2012 Phase 1
NCT00001082 National Institute of Allergy and Infectious Diseases (NIAID) Cytomegalovirus Infections|HIV Infections December 1996 Phase 3
NCT00095121 Gilead Sciences Chronic Hepatitis B June 2004 Phase 3
NCT00641082 Bukwang Pharmaceutical HBeAg(-) Chronic Hepatitis B With Compensated Liver Function February 2008 Phase 4
NCT00002128 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT00002426 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00002161 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00000843 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT00042393 Gilead Sciences Chronic Hepatitis B
NCT00455091 National Health Research Institutes, Taiwan|National Taiwan University Hospital|Chang Gung Memorial Hospital|Taipei Veterans General Hospital, Taiwan|Mackay Memorial Hospital|Taichung Veterans General Hospital|Changhua Christian Hospital|National Cheng-Kung University Hospital|Kaohsiung Veterans General Hospital.|Kaohsiung Medical University Hepatocellular Carcinoma May 2007
NCT00071201 Gilead Sciences Chronic Hepatitis B June 2003 Phase 3
NCT00753467 Huntington Medical Research Institutes|InterMune Hepatitis B September 2008 Phase 2
NCT00115245 Novartis|Novartis Pharmaceuticals Chronic Hepatitis B November 2004 Phase 3
NCT00187746 University of California, San Francisco Other Conditions That May Be A Focus of Clinical Attention August 2005 Phase 4
NCT00661076 Hoffmann-La Roche Hepatitis B, Chronic August 2008 Phase 3
NCT01146808 Columbia University|Gilead Sciences Hepatitis B|Liver Transplantation March 2006 Phase 1|Phase 2
NCT00002220 Merck Sharp & Dohme Corp.|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00606099 Novartis Chronic Hepatitis B November 2007 Phase 4
NCT00002419 Gilead Sciences|Glaxo Wellcome|Dupont Applied Biosciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00973219 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Chronic Hepatitis B September 2009
NCT00002219 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00002379 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT01300234 GlaxoSmithKline Hepatitis B March 2011 Phase 3
NCT00002398 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00002184 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00033163 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Hepatitis B Phase 2
NCT00376259 Novartis Hepatitis B January 2007 Phase 3
NCT00002234 Gilead Sciences|Bristol-Myers Squibb|Glaxo Wellcome|Dupont Applied Biosciences HIV Infections Phase 2
NCT00023153 National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) HIV Infections|Chronic Hepatitis B August 2001 Phase 3
NCT00672867 Bukwang Pharmaceutical Patients With LC-B December 2007 Phase 3
NCT00051077 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Hepatitis B|Hepatitis C Phase 2
NCT02075294 Ying-Jie Ji|Beijing 302 Hospital Hepatitis B, Chronic January 2010
NCT00002346 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT00371761 Merck Sharp & Dohme Corp. Hepatitis B, Chronic (CHB) September 2006 Phase 3
NCT02598063 Hoffmann-La Roche Hepatitis B, Chronic October 2005 Phase 4
NCT01521975 Third Affiliated Hospital, Sun Yat-Sen University|Guangdong Provincial People's Hospital|Guangzhou 8th People's Hospital Hepatitis B, Chronic September 2011 Phase 4
NCT01720238 Beijing Friendship Hospital|Peking University First Hospital|Peking University People's Hospital|Beijing YouAn Hospital|Beijing Tiantan Hospital|Beijing Ditan Hospital|Peking Union Medical College Hospital|Beijing 302 Hospital Liver Cirrhosis|Hepatitis B March 2012
NCT02327416 Tongji Hospital|Xiamen Amoytop Biotech Co., Ltd. Hepatitis B, Chronic October 2014 Phase 3
NCT00000892 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT02826070 Nanfang Hospital of Southern Medical University|Major Science and Technology Special Project of China Twelfth-Five-Year Project|Novartis Hepatitis B, Chronic April 2015 Phase 4
NCT00000912 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT01264354 Bukwang Pharmaceutical Chronic Hepatitis B March 2010 Phase 4
NCT02965859 Guangzhou Yipinhong Pharmaceutical CO.,LTD Chronic Hepatitis B December 2012 Phase 2
NCT00001087 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00000885 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00810524 Sun Yat-sen University Hepatitis B, Chronic January 2007 Phase 4
View MoreCollapse
References
M.Wt

501.47

Formula

C₂₀H₃₂N₅O₈P

CAS No.

142340-99-6

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Adefovir dipivoxil
Cat. No.:
HY-B0255
Quantity: